Table 2.
Various drug candidates that already associated with breast cancer via different sources.
| Drug name | Literature evidence | CTD | KEGG drug | Clinical trials |
|---|---|---|---|---|
| Epirubicin | Warm et al., 2010 | ✓ | ✓ | NCT00176488 |
| Erlotinib | Catania et al., 2006 | NCT01650506 | ||
| Lapatinib | Giampaglia et al., 2010 | ✓ | NCT00694252 | |
| Exemestane | Goss et al., 2013 | ✓ | ✓ | NCT00810797 |
| Wortmannin | Li et al., 2012 | ✓ | ||
| Alvocidib | Murphy and Dickler, 2015 | ✓ | NCT00039455 | |
| Tyrphostin ag 1478 | Zhang et al., 2008 | ✓ | ||
| Canertinib | Gschwantler-Kaulich et al., 2016 | ✓ | NCT00051051 | |
| Danazol | Coombes et al., 1983 | ✓ | ||
| Palbociclib | Finn et al., 2016 | ✓ | ✓ | NCT02513394 |